Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Daniel Edmonston Clear advanced filters
  • Oncolytic measles virus (MV) vaccine strains have shown preclinical antitumor activity against glioblastoma (GBM). Here the authors report the results of a phase 1 trial of intratumoral administration of a MV strain engineered to express the carcinoembryonic antigen in patients with recurrent GBM including assessment of viral replication and proinflammatory remodeling of the treated tumors.

    • Evanthia Galanis
    • Katharine E. Dooley
    • Ian F. Parney
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-12
  • CV2CoV, a second-generation mRNA COVID-19 vaccine with non-modified nucleosides but optimized non-coding regions, is demonstrated to be effective against SARS-CoV-2 challenge when tested in non-human primates.

    • Makda S. Gebre
    • Susanne Rauch
    • Dan H. Barouch
    ResearchOpen Access
    Nature
    Volume: 601, P: 410-414
  • The current COVID-19 pandemic is associated with unprecedented morbidity and mortality. Early reports suggested an association between disease severity and hypertension but did not account for sources of confounding. However, the responsible virus — SARS-CoV-2 — gains entry to host cells via angiotensin-converting enzyme 2 (ACE2), highlighting the need to understand the relationship between the virus and the renin–angiotensin system (RAS) and how this might be affected by RAS inhibitors.

    • Andrew M. South
    • Laurie Tomlinson
    • Matthew A. Sparks
    Comments & Opinion
    Nature Reviews Nephrology
    Volume: 16, P: 305-307
  • In this Review, the authors present an overview of the role of fibroblast growth factor 23 (FGF23) and klotho in normal mineral homeostasis, discuss disordered mineral homeostasis in chronic kidney disease (CKD), and explore CKD-associated FGF23 excess and klotho deficiency as novel risk factors and potential therapeutic targets for cardiovascular disease.

    • Daniel Edmonston
    • Alexander Grabner
    • Myles Wolf
    Reviews
    Nature Reviews Cardiology
    Volume: 21, P: 11-24
  • Fibroblast growth factor 23 (FGF23) is crucial to phosphate and calcium homeostasis. In this Review, the authors discuss how levels of biologically active FGF23 are controlled by balanced FGF23 transcription and protein cleavage, and how serum iron levels, inflammation and erythropoietin affect that balance.

    • Daniel Edmonston
    • Myles Wolf
    Reviews
    Nature Reviews Nephrology
    Volume: 16, P: 7-19